You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Delivery system development for a reservoir targeted Lyme disease vaccine
SBC: FoodSource Lure Corporation Topic: NIAIDDESCRIPTION (provided by applicant): The incidence and geographic distribution of Lyme disease in the U.S. has increased steadily since its first description in 1977. Efforts to stem the spread of the disease through controlling the population of its tickvector and/or the mouse reservoirs of the disease have met with only limited success. The only approved human vaccine to protect against Lyme di ...
STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of OCF001 for Treatment of Yeast Infections
SBC: Sano Chemicals, Inc. Topic: NIAIDProject Summary Occidiofungins (A-D) are cyclic nonribosomally synthesized antifungal peptides with submicromolar fungicidal activity against a broad spectrum of fungi. Optimization of the production and isolation of occidiofungins from liquid cultures has been performed. The production and isolation of predominantly one analog, called occidiofungin B (OCF001), supports its commercial development ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
HUCBC modulation of Alzheimer's-like pathology and behavioral changes
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NIADESCRIPTION (provided by applicant): In the past years, we have shown that human umbilical cord blood cells (HUCBC, U-CORD- CELL ) provide cognitive recovery in animal models of neurodegenerative disease. Infusion of HUCBC resulted in reduced infarct volume as well as in rescue of behavioral benefits in an animal model of stroke. We further showed that HUCBC infusion proved to be beneficial in ani ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Targeting glioblastoma stem-like cells with custom-designed viral vectors
SBC: Lacerta Therapeutics, Inc. Topic: 102Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
A Home Exercise Program (DVD) for Women with Infants and Young Children
SBC: KLEIN BUENDEL, INC. Topic: NIDADESCRIPTION (provided by applicant): Becoming a mother is a significant transition in a woman's life. This transition can precipitate major changes in health behaviors, like physical activity. Once a woman has a child she is much less likely to participate in regular, moderate to vigorous physical activity compared to women without children. Thus, new mothers are at risk for future weight gain and ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Acute-infarct selective cardiac MRI contrast agent
SBC: ELGAVISH PARAMAGNETICS, INC. Topic: NHLBIDESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes
SBC: Op-T-Mune, Inc Topic: NIAIDType 1 Diabetes (T1D) affects an ever growing population. While this disease typically has been associated with juveniles, the disease in adult populations is rapidly increasing. The defining clinical component is insulin loss, which occurs because of sustained inflammation in the islets. At present there is no means to prevent or reverse insulin loss. A major inflammatory pathway in T1D that cont ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic peanut allergen Fc gamma chimeric proteins to treat peanut allergy
SBC: TUNITAS THERAPEUTICS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): The overall goal of this Phase 2 STTR is to develop and commercialize a novel approach for allergen specific immunotherapy as a treatment for severe food allergy. Currently treatment to prevent severe food reactions isa major unmet need. There is no effective therapy, the only treatment being strict avoidance and emergency measures should an exposure occur. Th ...
STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
MyFAP: A Multimedia Intervention for Adolescents and Young Adults with FAP
SBC: Radiant Creative Group, LLC Topic: NCIDESCRIPTION (provided by applicant): In this Phase II STTR application, we will build upon work conducted in our successful Phase I project which established the technical merit, acceptability and feasibility of developing a Web-based intervention, MyFAP.org, for adolescents and young adults (AYAs) with familial adenomatous polyposis (FAP). The main research goal of Phase II is to evaluate the eff ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Conversations About cancer (CAC): A Theatrical Production
SBC: KLEIN BUENDEL, INC. Topic: NCIDESCRIPTION (provided by applicant): Findings from our Phase I feasibility study reveal strong impacts of a theatrical production we have developed entitled Conversations about Cancer (CAC): A play in which all dialogue is drawn from naturally occurring (transcribed) interactions between family members as they navigate their way through the trials and tribulations, hopes and triumphs of a cancer ...
STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health